Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Anne-Sophie Dugast"'
Autor:
Sivan Elloul, Anne-Sophie Dugast, Shannon McArdel, Enping Hong, Maegan Hoover, Laurence Turka, Zafira Castano, Arjun Reddy Bollampalli, Shannon Leonard, Ryan Pepi, Alex Nanna
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/305ceefb96694077a20dee7fde51ad88
Autor:
Deniz Cizmeci, Giuseppe Lofano, Evan Rossignol, Anne-Sophie Dugast, Dongkyoon Kim, Guy Cavet, Ngan Nguyen, Yann Chong Tan, Michael S Seaman, Galit Alter, Boris Julg
Publikováno v:
eLife, Vol 10 (2021)
A minor subset of individuals infected with HIV-1 develop antibody neutralization breadth during the natural course of the infection, often linked to chronic, high-level viremia. Despite significant efforts, vaccination strategies have been unable to
Externí odkaz:
https://doaj.org/article/742b0119745f4f6ba978c07e113f3df9
Autor:
M. Muenchhoff, A. W. Chung, J. Roider, Anne-Sophie Dugast, Simone Richardson, Henrik Kløverpris, Alasdair Leslie, Thumbi Ndung’u, Penny Moore, Galit Alter, Philip J. R. Goulder
Publikováno v:
mSphere, Vol 5, Iss 6 (2020)
ABSTRACT A prophylactic HIV vaccine would ideally induce protective immunity prior to sexual debut. Children develop broadly neutralizing antibody (bnAb) responses faster and at higher frequencies than adults, but little is known about the underlying
Externí odkaz:
https://doaj.org/article/f66d862dd1194fa4867e6134d3109279
Autor:
Sivan Elloul, Anne-Sophie Dugast, Shannon McArdel, Enping Hong, Arjun Bollampalli, Maegan Hoover, Sneha Pawar, Viral Amin, Kangjian Qiao, Christopher Ta, Laurence Turka, Thomas Wickham
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/8a6fd99397684961baede2a785881b1e
Autor:
Jenniffer M. Mabuka, Anne-Sophie Dugast, Daniel M. Muema, Tarylee Reddy, Yathisha Ramlakhan, Zelda Euler, Nasreen Ismail, Amber Moodley, Krista L. Dong, Lynn Morris, Bruce D. Walker, Galit Alter, Thumbi Ndung’u
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
Immunological events in acute HIV-1 infection before peak viremia (hyperacute phase) may contribute to the development of broadly cross-neutralizing antibodies. Here, we used pre-infection and acute-infection peripheral blood mononuclear cells and pl
Externí odkaz:
https://doaj.org/article/302b2597a0844697ad0819e0e3731b46
Autor:
Aimee M Merino, Anne-Sophie Dugast, Craig M Wilson, Paul A Goepfert, Galit Alter, Richard A Kaslow, Jianming Tang
Publikováno v:
PLoS ONE, Vol 9, Iss 6, p e99353 (2014)
KIR2DS4 gene variants encode full-length and truncated protein products, with only the former serving as membrane-bound receptors to activate natural killer (NK) cells. We have previously shown that full-length KIR2DS4 was associated with relatively
Externí odkaz:
https://doaj.org/article/c984b5c8c4f04010b8a9c35925626275
Autor:
Anne-Sophie Dugast, Ying Chan, Michelle Hoffner, Anna Licht, Joseph Nkolola, Hualin Li, Hendrik Streeck, Todd J Suscovich, Musie Ghebremichael, Margaret E Ackerman, Dan H Barouch, Galit Alter
Publikováno v:
PLoS ONE, Vol 9, Iss 5, p e97229 (2014)
Recent immune correlates analysis from the RV144 vaccine trial has renewed interest in the role of non-neutralizing antibodies in mediating protection from infection. While neutralizing antibodies have proven difficult to induce through vaccination,
Externí odkaz:
https://doaj.org/article/a3af037709d04423b28265a7eeaede41
Autor:
Andrew J. Sawyer, Daryl C. Drummond, Zhaohua Richard Huang, Eric Tam, Vasileios Askoxylakis, Gang Sun, Alexander Koshkaryev, Michael Santiago, Lia Luus, James F. Sampson, Ross B. Fulton, Stephanie Grabow, James J. Suchy, Anne-Sophie Dugast, Walid S. Kamoun
Supplemental figures 1, 2, and 3 and supplemental tables 1 and 2, showing the antitumor activity of EphA2-ILS-DTXp and the pharmacokinetics in multiple murine tumor models.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc53494c662779c87e655ae0c6423c80
https://doi.org/10.1158/1535-7163.22509429
https://doi.org/10.1158/1535-7163.22509429
Autor:
Andrew J. Sawyer, Daryl C. Drummond, Zhaohua Richard Huang, Eric Tam, Vasileios Askoxylakis, Gang Sun, Alexander Koshkaryev, Michael Santiago, Lia Luus, James F. Sampson, Ross B. Fulton, Stephanie Grabow, James J. Suchy, Anne-Sophie Dugast, Walid S. Kamoun
Combinations of chemotherapy with immunotherapy have seen recent clinical success, including two approvals of anti–PD-1/L1 agents in combination with taxane-based chemotherapy in non–small cell lung cancer and triple-negative breast cancer. Here,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb2072df5200a5c5f8144cbc7a5091df
https://doi.org/10.1158/1535-7163.c.6539295.v1
https://doi.org/10.1158/1535-7163.c.6539295.v1
Autor:
Alexander Koshkaryev, Walid S. Kamoun, Gang Sun, Vasileios Askoxylakis, Lia Luus, Ross B. Fulton, James F. Sampson, Eric M. Tam, Andrew J. Sawyer, Zhaohua Richard Huang, Daryl C. Drummond, Anne-Sophie Dugast, Michael Santiago, James Suchy, Stephanie Grabow
Publikováno v:
Molecular Cancer Therapeutics. 19:270-281
Combinations of chemotherapy with immunotherapy have seen recent clinical success, including two approvals of anti–PD-1/L1 agents in combination with taxane-based chemotherapy in non–small cell lung cancer and triple-negative breast cancer. Here,